People
Our people are what make Insmed what it is today.
Coming from a broad range of backgrounds and with a variety of technical, analytical and business capabilities, Insmed's staff is working to develop IPLEX into a therapy showing potential for the treatment of Myotonic Muscular Dystrophy (MMD) and Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease. Insmed has an experienced team with proven ability to develop recombinant protein products.
